Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of induction with arsenic trioxide or chemotherapy in a real-world cohort of patients with high-risk acute promyelocytic leukemia

24 Jun 2025

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Antioxidant Activity and Oxidative Stress
Share to Retinoids in leukemia and cellular processes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40555732
DOI: 10.1038/s41375-025-02663-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of induction with arsenic trioxide or chemotherapy in a real-world cohort of patients with high-risk acute promyelocytic leukemiaPMID 40555732Read ↗

Hepatotoxicity profile of single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia, its impact on clinical outcome and the effect of genetic polymorphisms on the incidence of hepatotoxicity.Semantic proximity Read ↗

Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemiaSemantic proximity Read ↗

Molecular Targets of Arsenic Trioxide in Malignant CellsSemantic proximity Read ↗

Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance.Semantic proximity Read ↗

Treatment of Acute Promyelocytic LeukemiaSemantic proximity Read ↗

Phase II Study of Single-Agent Arsenic Trioxide for the Front-Line Therapy of Acute Promyelocytic LeukemiaSemantic proximity Read ↗

Inhibition factors of arsenic trioxide therapeutic effects in patients with acute promyelocytic leukemia.Semantic proximity Read ↗

Optimal treatment strategies for high-risk acute promyelocytic leukemiaSemantic proximity Read ↗

Targeted Therapy Alone for Acute Promyelocytic LeukemiaSemantic proximity Read ↗

[Arsenic: The gold standard for acute promyelocytic leukaemia with FLT3-ITD mutation].Semantic proximity Read ↗

Early predictor for differentiation syndrome in newly diagnosed acute promyelocytic leukaemia patients treated with single-agent arsenic trioxideSemantic proximity Read ↗

Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.